Application of near-infrared fluorescence imaging in pancreatic cancer

doi:10.3877/cma.j.issn.2095-3232.2025.05.006

Abstract

Abstract:

Pancreatic cancer is one of the highly malignant tumors. Surgical resection remains the only effective treatment for patients with pancreatic cancer, saving the chance of cure and long-term survival. However, the overall prognosis of pancreatic cancer patients is extremely poor, and the 5-year survival rate of pancreatic cancer is less than 13%, mainly because it is difficult to be detected during the early stage. Early visualization of pancreatic tumors and early diagnosis of pancreatic cancer are the decisive factors for patients with pancreatic cancer to obtain long-term survival. Near-infrared fluorescence imaging is one of the key technologies to realize intraoperative navigation. In recent years, with gradual maturity of near-infrared-Ⅱ optical biological imaging theory, near-infrared-Ⅱ fluorescence imaging technology has become a research hotspot in the field of clinical surgical navigation. Despite of persistent technological progress in recent years, a series of practical problems remain unresolved. In this article, the progress in near-infrared fluorescence imaging in pancreatic cancer was reviewed, aiming to provide novel idea for precise diagnosis and treatment of pancreatic cancer.

Key words: Near infrared-Ⅱ fluorescence imaging, Pancreatic carcinoma, Photodynamic therapy

Yan Liao, Wei Cheng. Application of near-infrared fluorescence imaging in pancreatic cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(05): 693-699.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025.05.006

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I05/693

References 64

[1]	Chen J, Chen H, Zhang T, et al. Burden of pancreatic cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030[J]. Pancreatology, 2022, 22(5): 608-618. DOI: 10.1016/j.pan.2022.04.011.
[2]	Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades[J]. Ann Surg Oncol, 2012, 19(1): 169-175. DOI: 10.1245/s10434-011-1900-3.
[3]	Salem AI, Alfi M, Winslow E, et al. Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time?[J]. J Surg Oncol, 2015, 112(6): 643-649. DOI: 10.1002/jso.24048.
[4]	Leinwand J, Miller G. Regulation and modulation of antitumor immunity in pancreatic cancer[J]. Nat Immunol, 2020, 21(10): 1152-1159. DOI: 10.1038/s41590-020-0761-y.
[5]	Zhang Y, Zhang G, Zeng Z, et al. Activatable molecular probes for fluorescence-guided surgery, endoscopy and tissue biopsy[J]. Chem Soc Rev, 2022, 51(2): 566-593. DOI: 10.1039/d1cs00525a.
[6]	Luo X, Hu D, Gao D, et al. Metabolizable near-infrared-Ⅱ nanoprobes for dynamic imaging of deep-seated tumor-associated macrophages in pancreatic cancer[J]. ACS Nano, 2021, 15(6): 10010-10024. DOI: 10.1021/acsnano.1c01608.
[7]	Kang H, Shamim M, Yin X, et al. Tumor-associated immune-cell-mediated tumor-targeting mechanism with NIR-Ⅱ fluorescence imaging[J]. Adv Mater, 2022, 34(8): e2106500. DOI: 10.1002/adma.202106500.
[8]	Li Q, Chen K, Huang W, et al. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma[J]. Cancer Lett, 2021, 496: 169-178. DOI: 10.1016/j.canlet.2020.09.024.
[9]	Li D, Ushakova EV, Rogach AL, et al. Optical properties of carbon dots in the deep-red to near-infrared region are attractive for biomedical applications[J]. Small, 2021, 17(43): e2102325. DOI: 10.1002/smll.202102325.
[10]	Chen K, Li Q, Zhao X, et al. Biocompatible melanin based theranostic agent for in vivo detection and ablation of orthotopic micro-hepatocellular carcinoma[J]. Biomater Sci, 2020, 8(15): 4322-4333. DOI: 10.1039/d0bm00825g.
[11]	Chen X, Zeh HJ, Kang R, et al. Cell death in pancreatic cancer: from pathogenesis to therapy[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(11): 804-823. DOI: 10.1038/s41575-021-00486-6.
[12]	Shi Y, Gao W, Lytle NK, et al. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring[J]. Nature, 2019, 569(7754): 131-135. DOI: 10.1038/s41586-019-1130-6.
[13]	Chen PT, Wu T, Wang P, et al. Pancreatic cancer detection on CT scans with deep learning: a nationwide population-based study[J]. Radiology, 2023, 306(1): 172-182. DOI: 10.1148/radiol.220152.
[14]	Messmann H, Endlicher E, Gelbmann CM, et al. Fluorescence endoscopy and photodynamic therapy[J]. Dig Liver Dis, 2002, 34(10): 754-761. DOI: 10.1016/s1590-8658(02)80028-7.
[15]	Li H, Kim Y, Jung H, et al. Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy[J]. Chem Soc Rev, 2022, 51(21): 8957-9008. DOI: 10.1039/d2cs00722c.
[16]	Zhu S, Tian R, Antaris AL, et al. Near-infrared-Ⅱ molecular dyes for cancer imaging and surgery[J]. Adv Mater, 2019, 31(24): e1900321. DOI: 10.1002/adma.201900321.
[17]	Ang MJY, Chan SY, Goh YY, et al. Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics[J]. Adv Drug Deliv Rev, 2021, 178: 113907. DOI: 10.1016/j.addr.2021.113907.
[18]	Ovais M, Mukherjee S, Pramanik A, et al. Designing stimuli-responsive upconversion nanoparticles that exploit the tumor microenvironment[J]. Adv Mater, 2020, 32(22): e2000055. DOI: 10.1002/adma.202000055.
[19]	Zhang RR, Schroeder AB, Grudzinski JJ, et al. Beyond the margins: real-time detection of cancer using targeted fluorophores[J]. Nat Rev Clin Oncol, 2017, 14(6): 347-364. DOI: 10.1038/nrclinonc.2016.212.
[20]	Chen Y, Xue L, Zhu Q, et al. Recent advances in second near-infrared region (NIR-Ⅱ) fluorophores and biomedical applications[J]. Front Chem, 2021, 9: 750404. DOI: 10.3389/fchem.2021.750404.
[21]	Su Y, Yu B, Wang S, et al. NIR-Ⅱ bioimaging of small organic molecule[J]. Biomaterials, 2021, 271: 120717. DOI: 10.1016/j.biomaterials.2021.120717.
[22]	Gong F, Yang N, Wang X, et al. Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics[J]. Nano Today, 2020, 32: 100851. DOI: 10.1016/j.nantod.2020.100851.
[23]	Zhen W, An S, Wang S, et al. Precise subcellular organelle targeting for boosting endogenous-stimuli-mediated tumor therapy[J]. Adv Mater, 2021, 33(51): e2101572. DOI: 10.1002/adma.202101572.
[24]	Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]. Nature, 2019, 572(7769): 392-396. DOI: 10.1038/s41586-019-1456-0.
[25]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
[26]	Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer-clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540. DOI: 10.1038/s41571-020-0363-5.
[27]	Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet, 2020, 395(10242): 2008-2020. DOI: 10.1016/s0140-6736(20)30974-0.
[28]	Cox TR. The matrix in cancer[J]. Nat Rev Cancer, 2021, 21(4): 217-238. DOI: 10.1038/s41568-020-00329-7.
[29]	Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, et al. Paradigms on immunotherapy combinations with chemotherapy[J]. Cancer Discov, 2021, 11(6): 1353-1367. DOI: 10.1158/2159-8290.CD-20-1312.
[30]	Strobel O, Neoptolemos J, Jäger D, et al. Optimizing the outcomes of pancreatic cancer surgery[J]. Nat Rev Clin Oncol, 2019, 16(1): 11-26. DOI: 10.1038/s41571-018-0112-1.
[31]	Zhou B, Xu JW, Cheng YG, et al. Early detection of pancreatic cancer: where are we now and where are we going?[J]. Int J Cancer, 2017, 141(2): 231-241. DOI: 10.1002/ijc.30670.
[32]	Kasumova GG, Charles Conway W, Tseng JF. The role of venous and arterial resection in pancreatic cancer surgery[J]. Ann Surg Oncol, 2018, 25(1): 51-58. DOI: 10.1245/s10434-016-5676-3.
[33]	Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment[J]. Am J Pathol, 2019, 189(1): 44-57. DOI: 10.1016/j.ajpath.2018.09.009.
[34]	Dai M, Chen S, Teng X, et al. KRAS as a key oncogene in the clinical precision diagnosis and treatment of pancreatic cancer[J]. J Cancer, 2022, 13(11): 3209-3220. DOI: 10.7150/jca.76695.
[35]	Tao J, Yang G, Zhou W, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer[J]. J Hematol Oncol, 2021, 14(1): 14. DOI: 10.1186/s13045-020-01030-w.
[36]	Helms E, Kathrina Onate M, Sherman MH. Fibroblast heterogeneity in the pancreatic tumor microenvironment[J]. Cancer Discov, 2020, 10(5): 648-656. DOI: 10.1158/2159-8290.CD-19-1353.
[37]	Jia M, Zhang D, Zhang C, et al. Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy[J]. J Nanobiotechnology, 2021, 19(1): 384. DOI: 10.1186/s12951-021-01134-6.
[38]	Falcomatà C, Bärthel S, Schneider G, et al. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer[J]. Cancer Discov, 2023, 13(2): 278-297. DOI: 10.1158/2159-8290.CD-22-0876.
[39]	Huang X, Ding L, Liu X, et al. Regulation of tumor microenvironment for pancreatic cancer therapy[J]. Biomaterials, 2021, 270: 120680. DOI: 10.1016/j.biomaterials.2021.120680.
[40]	Wang X, Teh CSC, Ishizawa T, et al. Consensus guidelines for the use of fluorescence imaging in hepatobiliary surgery[J]. Ann Surg, 2021, 274(1): 97-106. DOI: 10.1097/SLA.0000000000004718.
[41]	Li D, Chen X, Wang D, et al. Synchronously boosting type-I photodynamic and photothermal efficacies via molecular manipulation for pancreatic cancer theranostics in the NIR-Ⅱ window[J]. Biomaterials, 2022, 283: 121476. DOI: 10.1016/j.biomaterials.2022.121476.
[42]	Geng X, Gao D, Hu D, et al. Active-targeting NIR-Ⅱ phototheranostics in multiple tumor models using platelet-camouflaged nanoprobes[J]. ACS Appl Mater Interfaces, 2020, 12(50): 55624-55637. DOI: 10.1021/acsami.0c16872.
[43]	Teng T, Lin R, Lin Z, et al. Photothermal augment stromal disrupting effects for enhanced Abraxane synergy chemotherapy in pancreatic cancer PDX mode[J]. Biomater Sci, 2020, 8(12): 3278-3285. DOI: 10.1039/d0bm00549e.
[44]	Kang H, Shamim M, Yin X, et al. Tumor-associated immune-cell-mediated tumor-targeting mechanism with NIR-Ⅱ fluorescence imaging[J]. Adv Mater, 2022, 34(8): e2106500. DOI: 10.1002/adma.202106500.
[45]	Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer[J]. Proc Natl Acad Sci USA, 2013, 110(50): 20212-20217. DOI: 10.1073/pnas.1320318110.
[46]	Pellico J, Gawne PJ, de Rosales RTM. Radiolabelling of nanomaterials for medical imaging and therapy[J]. Chem Soc Rev, 2021, 50(5): 3355-3423. DOI: 10.1039/D0CS00384K.
[47]	Zhen Z, Tang W, Chen H, et al. RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors[J]. ACS Nano, 2013, 7(6): 4830-4837. DOI: 10.1021/nn305791q.
[48]	Hu Y, Chi C, Wang S, et al. A comparative study of clinical intervention and interventional photothermal therapy for pancreatic cancer[J]. Adv Mater, 2017, 29(33): 1700448. DOI: 10.1002/adma.201700448.
[49]	Pham KY, Wang LC, Hsieh CC, et al. 1550 nm excitation-responsive upconversion nanoparticles to establish dual-photodynamic therapy against pancreatic tumors[J]. J Mater Chem B, 2021, 9(3): 694-709. DOI: 10.1039/d0tb02655g.
[50]	王吉荣. 基于铁死亡—化疗协同治疗的胰腺癌靶向脂质介孔二氧化硅纳米递送系统的构建及体内外抗肿瘤活性研究[D]. 上海: 中国人民解放军海军军医大学, 2023. DOI: 10.26998/d.cnki.gjuyu.2023.000263.
[51]	Rani R, Malik P, Dhania S, et al. Recent advances in mesoporous silica nanoparticle-mediated drug delivery for breast cancer treatment[J]. Pharmaceutics, 2023, 15(1): 227. DOI: 10.3390/pharmaceutics15010227.
[52]	Choi J, Sun IC, Sook Hwang H, et al. Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment[J]. Adv Drug Deliv Rev, 2022, 186: 114344. DOI: 10.1016/j.addr.2022.114344.
[53]	Liu Y, Wu X, Chen F, et al. Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies[J]. Biomaterials, 2022, 289: 121813. DOI: 10.1016/j.biomaterials.2022.121813.
[54]	Obaid G, Bano S, Thomsen H, et al. Remediating desmoplasia with EGFR-targeted photoactivable multi-inhibitor liposomes doubles overall survival in pancreatic cancer[J]. Adv Sci, 2022, 9(24): e2104594. DOI: 10.1002/advs.202104594.
[55]	Shi Y, Zhang J, Huang H, et al. Fe-doped polyoxometalate as acid-aggregated nanoplatform for NIR-Ⅱ photothermal-enhanced chemodynamic therapy[J]. Adv Healthc Mater, 2020, 9(9): e2000005. DOI: 10.1002/adhm.202000005.
[56]	Ji M, Xu M, Zhang W, et al. Structurally well-defined Au@Cu^2- x S core-shell nanocrystals for improved cancer treatment based on enhanced photothermal efficiency[J]. Adv Mater, 2016, 28(16): 3094-3101. DOI: 10.1002/adma.201503201.
[57]	Zhang F, Han X, Hu Y, et al. Interventional photothermal therapy enhanced brachytherapy: a new strategy to fight deep pancreatic cancer[J]. Adv Sci, 2019, 6(5): 1801507. DOI: 10.1002/advs.201801507.
[58]	Chen K, Yin B, Luo Q, et al. Endoscopically guided interventional photodynamic therapy for orthotopic pancreatic ductal adenocarcinoma based on NIR-Ⅱ fluorescent nanoparticles[J]. Theranostics, 2023, 13(13): 4469-4481. DOI: 10.7150/thno.84164.
[59]	Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation: a new cutting edge[J]. Nat Rev Cancer, 2013, 13(9): 653-662. DOI: 10.1038/nrc3566.
[60]	Hussain T, Nguyen QT. Molecular imaging for cancer diagnosis and surgery[J]. Adv Drug Deliv Rev, 2014, 66: 90-100. DOI: 10.1016/j.addr.2013.09.007.
[61]	韩梓瑜. Peptide-22-Cy7在胰腺癌光声成像及手术导航中的实验研究[D]. 广州: 南方医科大学, 2018.
[62]	Hu Z, Fang C, Li B, et al. First-in-human liver-tumour surgery guided by multispectral fluorescence imaging in the visible and near-infrared-Ⅰ/Ⅱ windows[J]. Nat Biomed Eng, 2020, 4(3): 259-271. DOI: 10.1038/s41551-019-0494-0.
[63]	Newton AD, Predina JD, Shin MH, et al. Intraoperative near-infrared imaging can identify neoplasms and aid in real-time margin assessment during pancreatic resection[J]. Ann Surg, 2019, 270(1): 12-20. DOI: 10.1097/SLA.0000000000003201.
[64]	Muilenburg KM, Isder CC, Radhakrishnan P, et al. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer[J]. Cancer Lett, 2023, 561: 216150. DOI: 10.1016/j.canlet.2023.216150.

Please choose a citation manager

Content to export